Background: Existing research links oxidative stress and inflammation to hair loss. Salvianolic acid B (SAB) is known for its anti-oxidative, anti-inflammatory, and other beneficial pharmacological properties. Objective: To assess the efficacy of SAB in modulating hair growth. Methods: In vivo experiments were conducted using C57BL/6 mice to evaluate the effects of SAB on hair and skin parameters. The study involved ex vivo analysis of human hair follicles (HFs) for hair shaft length and hair growth cycle assessment. In vitro, human dermal papilla cells (hDPCs) were cultured with SAB, and their proliferation, protection against H2O2-induced oxidative damage, and gene/protein expression alterations were examined using various analytical techniques, including Real-Time Cell Analysis (RTCA), DCFH-DA Assay, RNA-seq, and KEGG pathway analysis. Results: SAB treatment in mice significantly improved hair growth and vascularization by day 21. In human HFs, SAB extended hair shaft length and delayed the transition to the catagen phase. SAB-treated hDPCs showed a notable decrease in the expression of oxidation-antioxidation-related genes and proteins, including reduced phosphorylation levels of ERK and p38. Conclusion: The study indicates that SAB promotes hDPC proliferation and offers protection against oxidative stress, highlighting its potential as a therapeutic agent for enhancing hair growth and treating hair loss.
Rationale: Xanthelasma, characterized by yellowish plaques around the eyelids due to lipid deposits, is typically treated through invasive methods like laser therapy or surgery, which often leads to scarring and dyspigmentation. This case series investigates the potential of Zhuang medicine medicated thread moxibustion as a less invasive alternative. Patient Concerns: Three female patients, aged 34, 45, and 55, presented with non-tender, soft yellow plaques near the medial canthi of both upper eyelids. The lesions varied in size and had been present for durations ranging from 6 months to 2 years. These patients expressed concerns about the pain and potential adverse reactions associated with conventional treatments, opting instead for an alternative approach. Diagnoses: Each patient was diagnosed with xanthelasma based on clinical evaluation. Standard diagnostic tests returned normal results, confirming the absence of underlying systemic issues. Interventions: The treatment regimen involved Zhuang medicine medicated thread moxibustion applied at 10-day intervals for a total of three sessions. This traditional method was selected due to its minimally invasive nature. Outcomes: After the first session, patients experienced mild edema, which resolved within 24 h. A significant reduction in the size of the plaques was observed after the second session, and by the third session, there was complete resolution of the plaques. Throughout the treatment and follow-up period of 3 months, no adverse reactions or recurrence of the xanthelasma was noted. Lessons: This case series suggests that Zhuang medicine medicated thread moxibustion could be a safe and effective alternative for the treatment of xanthelasma, avoiding the complications associated with more invasive conventional methods. Further research involving larger sample sizes is recommended to validate these preliminary findings and possibly integrate this method into broader clinical practice.